Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody

Clinical Infectious Diseases

Volumn 44, Issue 2, 2007, Pages 204-212

  Peleg, Anton Y ^a,b   Husain, Shahid ^a   Kwak, Eun J ^a   Silveira, Fernanda P ^a   Ndirangu, Magdaline ^a   Tran, Jerry ^a   Shutt, Kathleen A ^a   Shapiro, Ron ^a   Thai, Ngoc ^a   Abu Elmagd, Kareem ^a   McCurry, Kenneth R ^a   Marcos, Amadeo ^a   Paterson, David L ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B LIPID COMPLEX; ATOVAQUONE; COTRIMOXAZOLE; CYTOKINE; DACLIZUMAB; DAPSONE; GANCICLOVIR; METHYLPREDNISOLONE; OKT 3; PENTAMIDINE; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASPERGILLOSIS; BALAMUTHIA MANDRILLARIS; BALAMUTHIA MANDRILLARIS INFECTION; BK VIRUS; BK VIRUS INFECTION; CONFIDENCE INTERVAL; CRYPTOCOCCOSIS; CYTOKINE RELEASE; CYTOKINE RELEASE SYNDROME; CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; EPSTEIN BARR VIRUS INFECTION; ESOPHAGUS CANDIDIASIS; FEBRILE VIRAL INFECTION; FEMALE; FEVER; GASTROINTESTINAL INFECTION; GRAFT FAILURE; GRAFT REJECTION; HEPATITIS; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 6 INFECTION; INTESTINE TRANSPLANTATION; INVASIVE ASPERGILLOSIS; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MOULD; MUCORMYCOSIS; MYCOBACTERIOSIS; MYCOBACTERIUM; MYCOSIS; NOCARDIA; NOCARDIOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; PARVOVIRUS INFECTION; PNEUMONIA; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROTOZOAL INFECTION; SCEDOSPORIUM INFECTION; SINGLE DRUG DOSE; SYNDROME; TOXOPLASMA GONDII; TOXOPLASMOSIS; TUBERCULOSIS; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; BACTERIAL INFECTIONS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOSES; ODDS RATIO; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION; RISK FACTORS; VIRUS DISEASES;

EID: 33846150015     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/510388     Document Type: Article

References (37)

1. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361:1502-10.
2. Tzakis AG, Tryphonopoulos P, Kato T, et al. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation 2004; 77: 1209-14.
3. Matas AJ, Kandaswamy R, Humar A, et al. Long-term immunosuppression, without maintenance prednisone, after kidney transplantation. Ann Surg 2004; 240:510-6; discussion 516-7.
4. Calne R, Moffatt SD, Friend PJ, et al. Campath 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999; 68:1613-6.
5. Knechtle SJ, Pirsch JD, Fechner JJ, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3:722-30.
6. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99:3554-61.
7. Ho AY, Pagliuca A, Kenyon M, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004; 104:1616-23.
8. McCurry KR, Iacono A, Zeevi A, et al. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg 2005; 130:528-37.
9. Basu A, Ramkumar M, Tan HP, et al. Reversal of acute cellular rejection after renal transplantation with Campath-1H. Transplant Proc 2005; 37:923-6.
10. Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years. Am J Transplant 2005; 5:1347-53.
11. Shapiro R, Ellis D, Tan HP, et al. Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J Pediatr 2006; 148:813-8.
12. Tzakis AG, Kato T, Nishida S, et al. Campath-1H in intestinal and multivisceral transplantation: preliminary data. Transplant Proc 2002; 34:937.
13. Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005; 200:505-15; quiz A59-61
14. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351:1701-2.
15. Knechtle SJ, Fernandez LA, Pirsch JD, et al. Campath-1H in renal transplantation: the University of Wisconsin experience. Surgery 2004; 136:754-60.
16. Kaufman DB, Leventhal JR, Gallon LG, Parker MA. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction- long-term results. Am J Transplant 2006; 6:331-9.
17. Vathsala A, Ona ET, Tan SY, et al. Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005; 80:765-74.
18. Marcos A, Eghtesad B, Fung JJ, et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2004; 78:966-71.
19. Tryphonopoulos P, Madariaga JR, Kato T, et al. The impact of Campath 1H induction in adult liver allotransplantation. Transplant Proc 2005; 37:1203-4.
20. Tzakis AG, Kato T, Nishida S, et al. Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. Transplantation 2003; 75:1512-7.
21. Thai NL, Abu-Elmagd K, Khan A, et al. Pancreatic transplantation at the University of Pittsburgh. Clin Transpl 2004:205-14.
22. Garcia M, Weppler D, Mittal N, et al. Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation. Transplant Proc 2004; 36:323-4.
23. Reams BD, Davis RD, Curl J, Palmer SM. Treatment of refractory acute rejection in a lung transplant recipient with Campath 1H. Transplantation 2002; 74:903-4.
24. Ruiz P, Soares MF, Garcia M, et al. Lymphoplasmacytic hyperplasia (possibly pre-PTLD) has varied expression and appearance in intestinal transplant recipients receiving Campath immunosuppression. Transplant Proc 2004; 36:386-7.
25. Ghobrial IM, Otteman LA, White WL. An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab. N Engl J Med 2003; 349:2570-2; discussion 2570-2.
26. Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006;43:16-24.
27. Thursky KA, Worth LJ, Seymour JF, Miles Prince H, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2006; 132:3-12.
28. Malek SK, Obmann MA, Gotoff RA, Foltzer MA, Hartle JE, Potdar S. Campath-1H induction and the incidence of infectious complications in adult renal transplantation. Transplantation 2006; 81:17-20.
29. Nath DS, Kandaswamy R, Gruessner R, Sutherland DE, Dunn DL, Humar A. Fungal infections in transplant recipients receiving alemtuzumab. Transplant Proc 2005; 37:934-6.
30. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6:262-74.
31. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
32. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med 1997; 156: S1-25.
33. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000; 161:1376-95.
34. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999;68:1517-25.
35. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6:1111-31.
36. Tzakis AG, Kato T, Levi DM, et al. 100 Multivisceral transplants at a single center. Ann Surg 2005; 242:480-90; discussion 491-3.
37. Bloom DD, Hu H, Fechner JH, Knechtle SJ. T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. Transplantation 2006; 81:81-7.